Klarna's valuation plunges 85% to $6.7B; Norway's DNB posts Q2 rate hike boost
S&P Global Market Intelligence's daily overview of essential Banking & Financials news in Europe.
www.spglobal.comI don’t have live access to current feeds in this moment. Here’s a concise summary of what’s been reported recently about Klarna Bank AB (publ) based on the latest public summaries I can reference up to now, and I can pull more details if you’d like.
Direct answer
- As of late 2025 and into 2026, Klarna has continued to publish annual/regulatory disclosures and press updates, including updates on GMV growth, income lines, and capital movements associated with internal funding steps. For precise latest headlines, I can fetch and summarize the most recent articles and official Klarna disclosures if you want.
Key recent themes to watch
- Valuation and fundraising context: Klarna has seen attention on its valuation trajectory and funding rounds as it positions itself for potential future public market steps. If you’re tracking this for investment or strategic purposes, I can pull the most current valuation references and any announced funding rounds.
- Regulatory and risk oversight: Finansinspektionen and other regulators have, in various periods, reviewed Klarna’s risk controls and credit risk governance. I can locate the latest regulator statements or inquiries to provide specifics on scope and status.
- Product and market expansion: Klarna has pursued broader banking-like services and cross-border expansion, with updates periodically published in its newsroom and regulatory filings. I can compile the newest announcements and their implications for users and merchants.
- Financial performance: Annual and quarterly reports show GMV trends, operating income, and profitability metrics, including any effects from strategic changes (e.g., divestitures or internal capital allocations). I can extract the latest figures and summarize year-over-year changes.
Would you like me to pull the most recent news articles and Klarna’s latest regulatory filings and provide a tightly cited summary with key figures and dates? If you have a preferred region (e.g., Europe-focused vs. U.S. market), I can tailor the recap.